Skip to content

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications 1

Clinical Trial: Bicillin L A vs Placebo for the Treatment of Chronic, Plaque Type Psoriasis Unresponsive to Topical Medications. The doctors have treated the patients of psoriasis by antibiotic drugs such as penicillin and azithromycin. Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications This study is currently recruiting participants. Study Type:Interventional: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: 2 (facet).

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications 2Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications. 2014-08-27 03:40:27 BioPortfolio. Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications Start of enrollment: 2007 Jan 01. Rosenberg, E. Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications clinicaltrials:NCT00427609.

33342. Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications. Therapy: Bicillin L-A. Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications ClinicalTrials.gov Identifier: NCT00427609 – Recruiting Psoriasis Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I ClinicalTrials. Topical lidocaine produces very low serum levels of active drug.

Bicillin L-a Vs Placebo For The Treatment Of Chronic, Plaque-type Psoriasis Unresponsive To Topical Medications

Octreotide Ivao